Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

被引：0

作者：

A. Luna

L. Pérez-Lamas

C. Boque

P. Giraldo

B. Xicoy

C. Ruiz Nuño

M. Moreno Vega

A. Alvarez-Larrán

A. Salamanca

A. García-Noblejas

F. Vall-Llovera

L. Villalon

N. De las Heras

E. Ramila

M. Pérez-Encinas

B. Cuevas

R. Perez-Lopez

F. Sanchez-Guijo

A. Jiménez-Velasco

S. Lakhwani

L. Felipe Casado

A. Rosell

A. Escola

M. J. Fernández

C. Garcia-Hernandez

C. Cervero

E. Mora

M. Sagüés

S. Suarez-Varela

P. Vélez

P. Carrascosa Mastell

R. F. Bitaube

L. Serrano

M. Cortes

J.A Vera Goñi

J. L. Steegmann

V. Gomez Garcia de Soria

J. M. Alonso-Dominguez

M. Colorado Araujo

A. Paz Coll

J.C Hernandez-Boluda

V. García-Gutiérrez

机构：

[1] Hospital Universitario Ramón y Cajal,Hematology Department

[2] IRYCIS,Institut Catala d’Oncologia

[3] Universidad de Alcala,Department of Medicine, University of Salamanca, Hematology Department

[4] Hospital Duran Y Reynals,undefined

[5] L’Hospitalet de Llobregat,undefined

[6] Hospital Quirón Zaragoza,undefined

[7] Institut Català d’Oncologia-Hospital Germans Trias I Pujol,undefined

[8] Hospital Regional Universitario de Málaga,undefined

[9] Hospital Doctor José Molina Orosa de Lanzarote,undefined

[10] Hospital Clinic de Barcelona,undefined

[11] Hospital de Jerez de La Frontera,undefined

[12] Hospital Universitario de La Princesa,undefined

[13] Hospital Mutua de Terrassa,undefined

[14] Hospital Universitario Fundación Alcorcón,undefined

[15] Hospital Universitario de León,undefined

[16] Hospital Parc Tauli,undefined

[17] Hospital Clínico Universitario de Santiago de Compostela,undefined

[18] Hospital Universitario de Burgos,undefined

[19] Hospital Universitario Clínico Virgen de La Arrixaca,undefined

[20] IBSAL-University Hospital of Salamanca,undefined

[21] Hospital Universitario Carlos Haya,undefined

[22] Hospital Universitario de Canarias,undefined

[23] Hospital Virgen de La Salud,undefined

[24] Hospital Virgen de La Victoria,undefined

[25] Hospital Provincial de Castellón,undefined

[26] Hospital Doctor Peset,undefined

[27] Hospital General de Alicante,undefined

[28] Hospital Virgen de La Luz,undefined

[29] Hospital Universitario Y Politécnico La Fe,undefined

[30] Hospital General de Castellón,undefined

[31] Hospital de Granollers,undefined

[32] Hospital Virgen Macarena,undefined

[33] Hospital Universitario Fundación Jiménez Díaz,undefined

[34] Hospital Universitario Marqués de Valdecilla,undefined

[35] Hospital Universitario Puerto Real,undefined

[36] Hospital Clínico Universitario-INCLIVA,undefined

[37] University of Valencia,undefined

来源：

Annals of Hematology | 2022年 / 101卷

关键词：

Leukemia; Inhibitors; Asciminib ;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.

引用

页码：2263 / 2270

页数：7

共 50 条

[41] Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/ Refractory Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL)
Jabbour, Elias
Oehler, Vivian G.
Koller, Paul B.
Jamy, Omer
Lomaia, Elza
Hunter, Anthony M.
Uspenskaya, Olga
Samarina, Svetlana
Mukherjee, Sudipto
Cortes, Jorge E.
Baer, Maria R.
Zherebtsova, Vera
Shuvaev, Vasily
Turkina, Anna
Davydkin, Igor
Guo, Huanshan
Chen, Zi
Fu, Tommy
Jiang, Lixin
Wang, Cunlin
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S371 - S371
[42] DISCONTINUING TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH MAJOR MOLECULAR RESPONSE: A REAL-LIFE EXPERIENCE
Dragani, M.
Fava, C.
Rege-Cambrin, G.
Ferrero, D.
Abbruzzese, E.
Pregno, P.
Cedrone, M.
Elena, C.
Santoro, M.
Cerrano, M.
Dogliotti, I.
Armenio, M.
Saglio, G.
HAEMATOLOGICA, 2018, 103 : S96 - S96
[43] RESULTS OF "REAL-LIFE" FRONTLINE DASATINIB TREATMENT IN UNSELECTED ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Latagliata, R.
Stagno, F.
Annunziata, M.
Iurlo, A.
Scappini, B.
Guarini, A.
Giglio, G.
Fava, C.
Sora, F.
Capodanno, I.
Crugnola, M.
Crescenzi, S. Leonetti
Barsotti, S.
Feo, C.
Breccia, M.
Vigneri, P.
Cambrin, G. Rege
Gozzini, A.
Alimena, G.
HAEMATOLOGICA, 2014, 99 : 604 - 604
[44] Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase
Haddad, Fadi G.
Sasaki, Koji
Senapati, Jayastu
Hu, Shimin
Dellasala, Sara
Issa, Ghayas C.
Jabbour, Elias
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04): : 254 - 257
[45] Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
Luna, Alejandro
Estrada, Natalia
Boque, Concepcion
Xicoy, Blanca
Giraldo, Pilar
Angona, Anna
Alvarez-Larran, Alberto
Sanchez-Guijo, Fermin
Ramirez, Maria Jose
Alonso-Dominguez, Juan M.
Mora, Elvira
Velez, Patricia
Rosell, Ana
Araujo, Mercedes Colorado
Cuevas, Beatriz
Sagues, Miguel
Cortes, Montserrat
Encinas, Manuel Perez
Montero, Luis Felipe Casado
Vega, Melania Moreno
Serrano, Luis
Gomez, Valle
Garcia-Hernandez, Carmen
Lakhwani, Sunil Lakhwani
Coll, Antonio Paz
de Paz, Raquel
Suarez-Varela, Sara
Fernandez-Ruiz, Andres
Lopez, Raul Perez
Ortiz-Fernandez, Almudena
Jimenez-Velasco, Antonio
Garcia-Gutierrez, Valentin
BLOOD, 2020, 136
[46] Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia
Eskazan, Ahmet Emre
Oztas, Mert
Bektas, Fatih
Sadri, Sevil
Keskin, Dilek
Yurttas, Nurgul Ozgur
Berk, Selin
Ozunal, Isil Erdogan
Salihoglu, Ayse
Ar, M. Cem
Ongoren, Seniz
Baslar, Zafer
Ozbek, Ugur
Aydin, Yildiz
Soysal, Teoman
BLOOD, 2016, 128 (22)
[47] PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL
Cortes, J.
Kim, D. W.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Mueller, M. C.
Gambacorti-Passerini, C.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
HAEMATOLOGICA, 2015, 100 : 64 - 64
[48] Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study
Heiblig, Mael
Rea, Delphine
Chretien, Marie-Lorraine
Charbonnier, Aude
Rousselot, Philippe
Coiteux, Valerie
Escoffre-Barbe, Martine
Dubruille, Vivian
Huguet, Francoise
Cayssials, Emilie
Hermet, Eric
Guerci-Bresler, Agnes
Ame, Shanti
Sackmann-Sala, Lucila
Roy, Lydia
Sobh, Mohamad
Morisset, Stephane
Etienne, Gabriel
Nicolini, Franck E.
EXPERIMENTAL HEMATOLOGY, 2018, 67 : 41 - 48
[49] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Kantarjian, Hagop M.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
BLOOD, 2013, 122 (21)
[50] Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia
Swaminathan, Mahesh
Kantarjian, Hagop M.
Sasaki, Koji
Ravandi, Farhad
Borthakur, Gautam
Kadia, Tapan M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Konopleva, Marina Y.
Estrov, Zeev E.
Pemmaraju, Naveen
Daver, Naval G.
Wierda, William G.
Ferrajoli, Alessandra
Pierce, Sherry A.
Dellasala, M. D. Emogene
Jabbour, Elias J.
Cortes, Jorge E.
BLOOD, 2018, 132

← 1 2 3 4 5 →